The National Core Facility for Biopharmaceuticals (NCFB) seeks to make efficient use of established research resources and provide professional high-tech service and expert consulting fulfilling the needs of academic and industrial PIs in Taiwan. The NCFB platform not only offers an excellent environment for the development of precision medicine, biotechnology, and pharmaceutical research, but also eases the transition from basic research to clinical trials.
NCFB complies with the strategy in the National Science and Technology Development Plan for establishing and sharing research infrastructure and resources. Guidance from the Bio Taiwan Committee (BTC), Discipline Development Meeting, and biopharmaceutical conferences are taken into consideration in the design of NCFB programs for the development of cutting-edge technologies and provision of high-quality services to industrial, medical, and academic users performing biopharmaceutical research. Implementation strategies include:
1.Integrating existing research resources and infrastructure: In order make efficient use of existing research resources, NCFB integrates the Core Facility Program for Biotechnology and Pharmaceuticals, resource centers developed under the National Research Program for Biopharmaceuticals, the National Core Facility Program for Biotechnology, and R&D teams developing forward-looking technologies in Taiwan under a new platform.
2.Developing cutting-edge technologies and providing professional high-tech service: NCFB takes the advantage of existing experience in cutting-edge technologies to provide professional high-tech service and expert consulting. Regular users’ committee meetings and annual reviews are conducted to meet the needs of academic and industrial researchers.
3.Promoting high-quality service for users in the biopharmaceutical community: In conjunction with government policies, the promotion of NCFB among industrial and academic users will be increased through official partnering, exhibitions, and conferences, which will ultimately lead to more collaboration between industry and academia. Enhanced dialogue between industry and academia fostered by NCFB will not only benefit personnel training and the technology transfer, but also sharpen the marketing trend sensitivity of academic scientists.
4.Accelerating upgrading of the biopharmaceutical industry in Taiwan: Universities' outstanding basic research capabilities will provide a solid foundation for the biopharmaceutical industry's development. NCFB has developed many advanced technologies in the field of biopharmaceuticals, and has encouraged the licensing of technology and patent applications. A "return on investment" concept has been incorporated in the management of NCFB core facilities. NCFB will provide support for the spin-off of those core facilities with potential to establish a research service company (RSC) or a contract research organization (CRO). This goal will be combined with science park occupancy (such as in the Nankang Biomedical Park) to strengthen basic R&D capabilities and optimize the environment for the transition from basic research to clinical trials within the biopharmaceutical industry.